Molecular Pathology of
Gliomas
Gliomas
|
Molecular Pathology of Gliomas |
| Home | • | About | • | Our Team | • | Expert Opinion | • | CuraBase Workspace | • | Contact |
|
| Affected Protein | Pathway | Sub-Type | Ethnicity | Stage | Frequency (%) | Gene Amplification | Activating Mutation | Inactivating Mutation | Deletion | Promoter Hypermethylation | Comment | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDM2 | p53 Tumor Suppressor Pathway |
astrocytoma | 6% | |||||||||
| p14ARF (CDKN2A) | p53 Tumor Suppressor Pathway |
anaplastic oligodendrogliomas (WHO grade III) | 25% | |||||||||
| p14ARF (CDKN2A) | p53 Tumor Suppressor Pathway |
oligodendrogliomas (WHO grade II) | 21% | |||||||||
| p16INK4a (CDKN2A) | Cell Cycle Regulation |
anaplastic oligodendrogliomas | 25% | |||||||||
| PTEN | PI3-Kinase Signaling |
low grade glioma | 43 -68% | associated with increased PKB/Akt phosphorylation |
| See Clinical Trials in in the TTC Database |